Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | polymerase (DNA directed) iota | Starlite/ChEMBL | No references |
Equus caballus | Ferritin light chain | Starlite/ChEMBL | No references |
Influenza A virus | Nonstructural protein 1 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Echinococcus multilocularis | expressed protein | Ferritin light chain | 175 aa | 146 aa | 30.1 % |
Schistosoma mansoni | ferritin | Ferritin light chain | 175 aa | 171 aa | 44.4 % |
Schistosoma mansoni | apoferritin-2 | Ferritin light chain | 175 aa | 146 aa | 28.8 % |
Echinococcus granulosus | expressed protein | Ferritin light chain | 175 aa | 146 aa | 28.8 % |
Schistosoma japonicum | Ferritin, putative | Ferritin light chain | 175 aa | 144 aa | 24.3 % |
Mycobacterium tuberculosis | Hypothetical protein | Nonstructural protein 1 | 230 aa | 202 aa | 23.8 % |
Schistosoma mansoni | ferritin | Ferritin light chain | 175 aa | 171 aa | 43.9 % |
Schistosoma mansoni | apoferritin-2 | Ferritin light chain | 175 aa | 142 aa | 29.6 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Entamoeba histolytica | hypothetical protein | 0.006 | 0.12 | 1 |
Trypanosoma cruzi | ferric reductase transmembrane protein, putative | 0.021 | 0.6112 | 1 |
Echinococcus granulosus | Basic leucine zipper bZIP transcription | 0.004 | 0.0562 | 1 |
Leishmania major | ferric reductase, putative | 0.021 | 0.6112 | 1 |
Schistosoma mansoni | transcription factor LCR-F1 | 0.004 | 0.0562 | 1 |
Entamoeba histolytica | hypothetical protein | 0.004 | 0.0562 | 0.468 |
Schistosoma mansoni | hypothetical protein | 0.004 | 0.0562 | 1 |
Brugia malayi | hypothetical protein | 0.004 | 0.0562 | 0.0562 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription | 0.004 | 0.0562 | 1 |
Treponema pallidum | hypothetical protein | 0.006 | 0.12 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0119 | 0.3124 | 0.3124 |
Entamoeba histolytica | hypothetical protein | 0.004 | 0.0562 | 0.468 |
Entamoeba histolytica | hypothetical protein | 0.004 | 0.0562 | 0.468 |
Trypanosoma brucei | ferric reductase transmembrane protein, putative | 0.021 | 0.6112 | 1 |
Entamoeba histolytica | hypothetical protein | 0.004 | 0.0562 | 0.468 |
Trypanosoma cruzi | ferric reductase transmembrane protein, putative | 0.021 | 0.6112 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (binding) | = 7.9433 um | PUBCHEM_BIOASSAY: qHTS Assay for Identification of Novel General Anesthetics. In this assay, a GABAergic mimetic model system, apoferritin and a profluorescent 1-aminoanthracene ligand (1-AMA), was used to construct a competitive binding assay for identification of novel general anesthetics (Class of assay: confirmatory) [Related pubchem assays: 2385 (Probe Development Summary for Identification of Novel General Anesthetics), 2323 (Validation apoferritin assay run on SigmaAldrich LOPAC1280 collection)] | ChEMBL. | No reference |
Potency (functional) | 10 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Potency (functional) | = 12.5893 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Influenza NS1 Protein Function. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.